Clinical trial NCT03418805: To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers
Official title: A Randomized, 4-way Crossover Study to Evaluate the Food Effect and the Absorption Profile of Investigational Product of "Ibuprofen Controlled-Release Tablets 600 mg" in Comparison to the Reference Standard Ibuprofen Tablets 200 mg in Normal Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Pain Control
Keywords: Ibuprofen
Controlled-Release
pain control
Healthy Volunteers
Food Effect
Lead sponsor: Overseas Pharmaceuticals, Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Virginia Contract Research Organization Co., Ltd.
First posted: 2018-02-01
Enrollment: 31
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To evaluate the food effect of Ibuprofen CR Tablets 600 mg (IBUCR), and its bioavailability comparison versus 3 doses of the reference arms including Advil® Ibuprofen Tablets 200 mg (IBUAdv) and Motrin® IB Ibuprofen Tablets 200 mg (IBUMot) in normal healthy volunteers.

Detailed description: This randomized, open label, four-way crossover phase I study is to evaluate the food effect of Ibuprofen CR Tablets 600 mg (IBUCR), and its bioavailability comparison versus 3 doses of the reference arms including Advil® Ibuprofen Tablets 200 mg (IBUAdv) and Motrin® IB Ibuprofen Tablets 200 mg (IBUMot) in normal healthy volunteers.

This study will enroll at least 26 evaluable subjects. The duration for test and reference treatments is 24 to 32 hours with a washout period of at least 5 days after the last dose administration of study drugs. The total study will take at least 28 days.

Subjects who meet all eligible requirements for participating in the study will receive all following interventions according to one of the 4 random sequences by Williams design.

1. One tablet of IBUCR 600 mg under fasting condition
2. One tablet of IBUCR 600 mg under fed condition
3. IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
4. IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition

The blood sampling schedule are described as follows:

-For subjects receiving IBUCR (fed and fasted): Before dose administration (blank) and at 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 18h, 24h, 28h, 32h post-dose (A total of 17 samples per subject)

-For subjects receiving IBUAdv/IBUMot (fasted): Before dose administration (blank) and at 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 8h, 8.5h, 9h, 9.5h, 10h, 10.5h, 11h, 12h, 16h, 20h, 24h post-dose (A total of 25 samples per subject)

Eligibility criteria: Inclusion Criteria:

1. Subjects are 20 years of age or older.
2. Subjects whose body mass index (BMI) at screening is within a range of ≧18.5 kg/m2 and \<25.0 kg/m2.

   BMI = Body Weight (kg) / \[Height (m)\]2 And body weight is not less than 50 kg and 45 kg for males and females, respectively.
3. Subject's medical history shows no contraindication to the test medications (hypersensitivity to ibuprofen or any component of test and reference products).
4. Subjects who are judged to be in good health by the investigator based upon the results of physical examinations (PEs), chest X-ray (within 180 days prior to the first dose of the study) and routine laboratory tests.
5. The female subject shows negative pregnancy test results within 30 days prior to the first dose of the study.
6. The Subject did not take any of the following medications in the specified durations:

   * Any medication within 14 days prior to the first dose of the study
   * Any enzyme inducer or inhibitor within 30 days prior to the first dose of the study
7. Subject understood and has signed the written informed consent form.

Exclusion Criteria:

1. Subjects with any properly diagnosed disease within 30 days prior to the first dose of the study.
2. Subjects with a clinically significant hematological, endocrine, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorder; subjects with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of drugs; subjects who has had any previous gastrointestinal surgery, except appendectomy if performed \>90 days prior to the first dose of the study
3. Subjects who require treatment with any medications, either prescription or non-prescription (excluding vitamins and food supplements), within 30 days prior to the first dose of the study
4. Subjects who have received any known hepatic or renal clearance-altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazine, clarithromycin, trolearndomycin, ketoconazole, miconazole, fluconazole, itraconazole) for a period of up to 30 days prior to the first dose of the study
5. The subject had participated in investigational drug trials and took any investigational drug within 60 days prior to the first dose of the study.
6. The subject had blood donation more than 250 and 500 mL within 60 and 90 days, respectively prior to the first dose of the study.
7. The subject had a history of drug abuse or alcohol abuse.
8. Subjects cannot stop smoking and caffeine-intakes for 48 hours prior to the first dose of the study and during the entire study period.
9. Subjects who are pregnant or lactating
10. For enrollment of female subjects with child-bearing potential, the subject must be practicing sexual abstinence or be using and willing to continue to use a medically acceptable form of birth control for at least 30 days prior to screening (that period will extend to 3 months for oral contraceptive use) and for at least 30 days after the last dose of study drug. For a subject to be considered not to be of child-bearing potential, she must have been amenorrheic for at least 2 years, or must have had a hysterectomy, a bilateral tubal ligation, and/or a bilateral oophorectomy (as determined by the medical history). The male partner of a female study subject with childbearing potential must use a condom and ensure that his partner uses a suitable method of contraception as outlined above.
11. Subjects who are inappropriate to participate in this study, as judged by the medical investigator or sub-investigator
12. Subjects with any contraindication to the use of test medications
13. Subjects who are carriers of hepatitis B virus, hepatitis C virus, or are syphilis (STS) positive, or human immunodeficiency virus (HIV) positive

Primary outcomes:
measure: Area under the curve from time zero to the time of the last quantifiable plasma concentration of the period (AUC0-last)
timeFrame: 1 month
measure: Area under the curve from time zero to infinity (AUC0-inf)
timeFrame: 1 month
measure: Peak concentration at each treatment period (Cmax,tp)
timeFrame: 1 month
Secondary outcomes:
measure: Peak concentration of the first dosing (Cmax)
timeFrame: 1 month
measure: Time to reach peak concentration of the first dosing (Tmax)
timeFrame: 1 month
measure: Terminal half-life (T1/2)
timeFrame: 1 month
measure: Mean residence time (MRT)
timeFrame: 1 month
measure: The maximum ibuprofen plasma concentration within 1 hour after the first dose administration (Cmax0-1h)
timeFrame: 0.5h and 1h post-dose
measure: The minimum ibuprofen plasma concentration within a time window of 1-12 hours after the first dose administration (Cmin1-12h)
timeFrame: 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h and 12h post-dose
measure: The mean time to drop to the Cmin1-12h of reference treatments
timeFrame: 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 12h, 18h, 24h, 28h, 32h post-dose
measure: Plasma ibuprofen concentrations at 8-hour (C8h) after the first dose administration
timeFrame: 8-hour after the first dose administration
measure: Plasma ibuprofen concentrations at 12-hour (C12h) after the first dose administration
timeFrame: 12-hour after the first dose administration
measure: Percentage of the test drug-treated subjects with higher or equal C8h compared to that of receiving the reference treatments (before dose 3) under fasting condition
timeFrame: 1 month
measure: Percentage of the test drug-treated subjects with higher or equal C12h compared to that of receiving the reference treatments under fasting condition
timeFrame: 1 month
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital
Study officials:
References: